MINNEAPOLIS--(BUSINESS WIRE)--Medtronic Inc. (NYSE:MDT) today announced the first clinical implants in the United States of the Medtronic Attain Ability™ over-the-wire lead (Model 4196), a dual-electrode left ventricular (LV) lead for use in heart failure patients with cardiac resynchronization therapy (CRT) devices. These implantable devices are used to resynchronize the heart’s ventricles to help pump blood more effectively through the body.
